Health

Subcommittee

Subcommittee on Health

The health sector broadly, including private and public health insurance (Patient Protection and Affordable Care Act, Medicare, Medicaid, CHIP); biomedical research and development; hospital construction; mental health; health information technology, privacy, and cybersecurity; medical malpractice and medical malpractice insurance; the 340B drug discount program; the regulation of food, drugs, and cosmetics; drug abuse; the Department of Health and Human Services; the National Institutes of Health; the Centers for Disease Control; Indian Health Service; and all aspects of the above-referenced jurisdiction related to the Department of Homeland Security.

Subcommittees News & Announcements


Jan 14, 2025
Press Release

Chairman Guthrie Announces 119th Energy and Commerce Republican Subcommittee Assignments

WASHINGTON, D.C.  – Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, announced subcommittee membership for the 119 th  Congress. “Today, I am proud to announce the House Committee on Energy and Commerce subcommittee assignments for the 119 th Congress,”   said Chairman Guthrie.   “Energy and Commerce Republicans are ready to hit the ground running, delivering for President Trump’s America First agenda to restore the American Dream.” The Subcommittee Rosters are as follows: Subcommittee on  Communications and Technology: Rep. Richard Hudson (NC-09), Chairman Rep. Rick Allen (GA-12), Vice Chairman Rep. Bob Latta (OH-05) Rep. Gus Bilirakis (FL-12) Rep. Buddy Carter (GA-01) Rep. Neal Dunn (FL-02) Rep. John Joyce (PA-13) Rep. Russ Fulcher (ID-01) Rep. August Pfluger (TX-11) Rep. Kat Cammack (FL-03) Rep. Jay Obernolte (CA-23) Rep. Erin Houchin (IN-09) Rep. Russell Fry (SC-07) Rep. Tom Kean, Jr. (NJ-07)  Rep. Craig Goldman (TX-12) Rep. Julie Fedorchak (ND-AL) Rep. Brett Guthrie (KY-02), Ex-Officio Subcommittee on  Energy: Rep. Bob Latta (OH-05), Chairman Rep. Randy Weber (TX-14), Vice Chairman Rep. Gary Palmer (AL-06) Rep. Rick Allen (GA-12) Rep. Troy Balderson (OH-12) Rep. August Pfluger (TX-11) Rep. Diana Harshbarger (TN-01) Rep. Mariannette Miller-Meeks (IA-01) Rep. John James (MI-10) Rep. Cliff Bentz (OR-02) Rep. Russell Fry (SC-07) Rep. Laurel Lee (FL-15) Rep. Nick Langworthy (NY-23) Rep. Michael Rulli (OH-06) Rep. Gabe Evans (CO-08) Rep. Craig Goldman (TX-12) Rep. Julie Fedorchak (ND-AL) Rep. Brett Guthrie (KY-02), Ex-Officio Subcommittee on  Health: Rep. Buddy Carter (GA-01), Chairman Rep. Neal Dunn (FL-02), Vice Chairman Rep. Morgan Griffith (VA-09) Rep. Gus Bilirakis (FL-12) Rep. Dan Crenshaw (TX-02) Rep. John Joyce (PA-13) Rep. Troy Balderson (OH-12) Rep. Diana Harshbarger (TN-01) Rep. Mariannette Miller-Meeks (IA-01) Rep. Kat Cammack (FL-03) Rep. Jay Obernolte (CA-23) Rep. John James (MI-10) Rep. Cliff Bentz (OR-02) Rep. Erin Houchin (IN-09) Rep. Nick Langworthy (NY-23) Rep. Tom Kean, Jr. (NJ-07)  Rep. Michael Rulli (OH-06) Rep. Brett Guthrie (KY-02), Ex-Officio Subcommittee on  Environment: Rep. Morgan Griffith (VA-09), Chairman Rep. Dan Crenshaw (TX-02), Vice Chairman Rep. Bob Latta (OH-05) Rep. Buddy Carter (GA-01) Rep. Gary Palmer (AL-06) Rep. John Joyce (PA-13) Rep. Randy Weber (TX-14) Rep. August Pfluger (TX-11) Rep. Mariannette Miller-Meeks (IA-01) Rep. Laurel Lee (FL-15) Rep. Nick Langworthy (NY-23) Rep. Gabe Evans (CO-08) Rep. Julie Fedorchak (ND-AL) Rep. Brett Guthrie (KY-02), Ex-Officio Subcommittee on  Oversight & Investigations: Rep. Gary Palmer (AL-06), Chairman Rep. Troy Balderson (OH-12), Vice Chairman Rep. Morgan Griffith (VA-09) Rep. Neal Dunn (FL-02) Rep. Dan Crenshaw (TX-02) Rep. Randy Weber (TX-14) Rep. Rick Allen (GA-12) Rep. Russ Fulcher (ID-01) Rep. Michael Rulli (OH-06) Rep. Brett Guthrie (KY-02), Ex-Officio Subcommittee on Commerce, Manufacturing, & Trade: Rep. Gus Bilirakis (FL-12), Chairman Rep. Russ Fulcher (ID-01), Vice Chairman Rep. Diana Harshbarger (TN-01) Rep. Kat Cammack (FL-03) Rep. Jay Obernolte (CA-23) Rep. John James (MI-10) Rep. Cliff Bentz (OR-02) Rep. Erin Houchin (IN-09) Rep. Russell Fry (SC-07) Rep. Laurel Lee (FL-15) Rep. Tom Kean, Jr. (NJ-07)  Rep. Gabe Evans (CO-08) Rep. Craig Goldman (TX-12)  Rep. Brett Guthrie (KY-02), Ex-Officio ###



Jan 6, 2025
Press Release

Chairman Guthrie Announces House Committee on Energy and Commerce Subcommittee Chief Counsels

WASHINGTON, D.C.  – Today, Congressman Brett Guthrie (KY-02), Chairman of the House Committee on Energy and Commerce, announced the Committee’s Subcommittee Chief Counsels for the 119th Congress: Subcommittee on Communications and Technology  Chief Counsel - Kate Harper Kate O’Connor Harper will serve as Chief Counsel for the Subcommittee on Communications and Technology, where she has served for the past 5 years. Kate previously served as the Chief of Staff for the National Telecommunications and Information Administration, where she worked on legislative and communications policy focused on spectrum and broadband issues. She also worked in NTIA’s Office of Congressional Affairs and engaged with Congress, state government officials, and other federal agencies to advance the Administration’s legislative initiatives on broadband and 5G. Subcommittee on Commerce, Manufacturing, and Trade Chief Counsel - Giulia Leganski Giulia Leganski will serve as Chief Counsel for the Subcommittee on Commerce, Manufacturing, and Trade. Prior to this role, Giulia served as a Professional Staff Member for the Subcommittee on Communications and Technology, handling issues related to Big Tech, Section 230, Artificial Intelligence, cybersecurity, media, and public safety. Previously, Giulia worked as a Professional Staff Member for the House Small Business Committee, as Acting Deputy Assistant Secretary for Legislative Affairs at the U.S. Department of State, and in the White House Office of Legislative Affairs.  Subcommittee on Energy  Chief Counsel - Mary K. Martin Mary K. Martin will serve as Chief Counsel for the Subcommittee on Energy. Prior to her years at Energy and Commerce, Mary previously served as policy counsel and committee executive to the Environment, Technology & Regulatory Affairs Division at the U.S. Chamber of Commerce. Before joining the Chamber, Mary spent 10 years as an attorney in private practice litigating complex commercial disputes, including environmental contamination, toxic tort, breach of contract, and insurance coverage matters. Most recently, Mary served as Of Counsel at Steptoe & Johnson LLP in Washington, D.C.  Subcommittee on Environment  Chief Counsel - Jake Tyner  Jake Tyner will serve as Chief Counsel for the Subcommittee on Environment. Jake has extensive Capitol Hill experience, most recently serving as General Counsel for Senator Dan Sullivan. In this role, Jake led the Senator’s efforts on issues related to energy, then environment, natural resources, and permitting and regulatory reform. Prior to joining Senator Sullivan’s office, Jake worked for Congressman David McKinley of West Virginia, the ranking member on the Environment & Climate Change Subcommittee in the U.S. House of Representatives and at the U.S. Chamber of Commerce. Subcommittee on Health Chief Counsel - Jay Gulshen Jay Gulshen will serve as Chief Counsel for the Subcommittee on Health. Jay most recently served as a Senior Health Advisor for the Committee on Energy and Commerce, working on Medicare Part B and Part D. Prior to returning to Energy and Commerce, Jay worked for the Committee on Ways and Means, advising on Medicare Parts A and B, served as the Health Policy Advisor for Congressman Buddy Carter, and as a Legislative Associate for the Energy and Commerce’s Health Subcommittee. Subcommittee on Oversight & Investigations  Chief Counsel - Brittany Havens Brittany Havens will serve as Chief Counsel for the Subcommittee on Oversight and Investigations. Prior to this role, Brittany served as a Senior Oversight Counsel on the Committee on Ways and Means Oversight Subcommittee working on a variety of issues, including oversight of federal agencies and programs; oversight of the tax-exempt sector; and legislation related to matters of tax administration. Prior to that, Brittany served in various roles for the Committee on Energy and Commerce between 2012 - 2022, most recently as a Professional Staff Member, conducting oversight on a wide range of topics within the Committee’s jurisdiction. The House Committee on Energy and Commerce Subcommittee staff will work under the direction of Staff Director Megan Jackson, Deputy Staff Director Sophie Khanahmadi, and Chief Counsel Joel Miller.



Dec 20, 2024
Press Release

Investigation Report Details HHS Secretary’s Failures on Reappointment of Key NIH Officials putting Agency Work and Personnel in Legal Jeopardy

Focus on Inferior Officer Appointments and Political Accountability Heightened as Transition in Administration Begins Washington, D.C. — In a new report issued by House Energy and Commerce Committee Republican staff outlined Department of Health and Human Services (HHS) Secretary Xavier Becerra’s failure to legally reappoint 14 key officials at the National Institutes of Health (NIH). “Secretary Becerra, an attorney by trade, failed to sign the basic legal documents and follow the process required by the Constitution and federal law necessary to reappoint key NIH officials, putting their jobs, the decisions they’ve made, and the billions in funding they’ve approved in legal jeopardy,” said Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), and Oversight and Investigations Chair Morgan Griffith (R-VA). “This report outlines those failures, the administration’s efforts to cover it up, and important considerations for the incoming administration as it seeks to restore the rule of law and restore accountability at government health institutions.”  BACKGROUND AND TIMELINE OF INVESTIGATION :  The NIH is the primary agency of the United States government responsible for biomedical and public health research. It is one of 13 subcabinet agencies within the HHS and has an annual budget of more than $40 billion.  On December 12, 2021, the five-year terms of 14 of the 27 NIH Institute and Center (IC) Directors expired, pursuant to the 21st Century Cures Act .  Given reports of Secretary Becerra’s apparent detachment from the NIH and lack of visibility during the pandemic response as well as the lack of any public announcements, Committee Republicans began to question whether Secretary Becerra upheld his Constitutional and statutory responsibility to reappoint the 14 IC Directors upon expiration of their five-year terms.  Republicans investigated for more than two years, overcoming stonewalling, obfuscation, and four different, conflicting explanations from the administration.  WHY IT MATTERS :  The appointments and reappointments of IC Directors are personnel actions that rise to the level of Constitutional responsibility further bolstered by federal statutes. The leaders of these institutes and centers are the ultimate decision-makers involving tens of billions of taxpayer-funded research dollars. These leaders also can play prominent roles in response to public health emergencies or in developing research plans. The effectiveness of biomedical research investments depends on the decision-making abilities and strategic visions of these IC Directors.  The health of the American people is deeply impacted by the appointees who lead the NIH’s institutes and centers. Because the Directors of NIH Institutes and Centers exercise significant authority as the final approving authority for research awards, they would qualify as Inferior Officers of U.S. who must be appointed by the HHS Secretary pursuant to the Appointments Clause of the U.S. Constitution along with the provisions of the 21st Century Cures Act . Greater democratic accountability requires department heads to be responsible for properly managing their agencies in the best interest of the public. Holding department heads accountable for the staffing of executive agencies improves accountability and transparency.   1. Improper appointments jeopardize good stewardship of funds  Improper appointments and reappointments potentially expose the actions of the improperly appointed IC Directors to legal challenge and jeopardizes the proper administration of research funds.   2. Improper appointments risk legal challenge to IC hiring and policies Improper appointments and reappointments potentially expose any personnel actions approved by the improperly appointed IC Directors to legal challenge.  3. Improper appointments may have led to improper payment of Title 42 special consultant salaries  During the year and a half of their lapsed reappointments, the affected IC Directors continued on the NIH payroll and received salaries even though they were serving without the legal authority to hold their positions. This situation raises the question of improper payments of salaries. In a 1976 opinion, the GAO Comptroller General concluded that the Federal Insurance Administrator was improperly appointed and that the appointment required Presidential nomination and Senate confirmation pursuant to the Appointments Clause.   In a subsequent opinion, the GAO Comptroller General found that the Federal Insurance Administrator was not legally occupying the position and thus was not entitled to receive salary and related benefits from the Department. GAO then concluded that this official was a de facto officer, performing his duties of the Office of Insurance Administrator with the knowledge and apparent acquiescence of the Secretary and the President. GAO concluded it was not necessary to take action to recover the salary. However, whether an NIH or HHS official who approved an expenditure of funds without legal authority could be held liable for the funds is an open question.  4. Secretary Becerra violated his oath by failing to carry out his Appointments Clause responsibilities.  When he was sworn in as HHS Secretary, Secretary Becerra took his oath of office swearing to support and defend the Constitution of the United States, including the Appointments Clause. By failing to reappoint the IC Directors pursuant to the Appointment Clause, Secretary Becerra failed to uphold the Appointments Clause until he was pressured by the Committee to issue signed affidavits ratifying the selections for reappointments a year and a half after the statutory deadline. During that time lapse the individuals serving as IC Directors were holding their positions without valid reappointments.  5. IC Directors serving without valid reappointments further undermined public trust in public health leadership.  Public trust in the federal government’s health leadership was eroded during the response to the COVID-19 pandemic. The public trust is further damaged by the fact that some public health leaders cloaked in the authority of their titles were not legally authorized to hold those positions. Ensuring proper appointments and reappointments to these offices is yet an additional challenge to restore public trust. Secretary Becerra’s failure raises questions whether the American people can assume that public health leaders actually have competent authority to act during a public health emergency.  6. The failure to take seriously the reappointments of the IC Directors subverts the rule of law. The failure to take seriously the reappointments of the IC Directors subverts the rule of law. In this instance, the law called for precision: the HHS Secretary reappointing of IC Directors by a certain date. The action to be taken was to fulfill the Constitutional duty and the statutory requirement to reappoint Inferior Officers of the United States. HHS’s lax approach toward this matter and its evasive, frequently misleading responses to this investigation reveals a lack of diligence in upholding the rule of law and our democratic values. The cavalier attitude toward following the law and the Constitution as well as the subsequent attempts at hiding its failure to follow the law is a prime example of the Biden-Harris administration’s above-the-law attitude and approach to governing.  CLICK HERE to read the full report.


Subcommittee Members

(32)

Chairman Health

Buddy Carter

R

Georgia – District 1

Vice Chairman Health

Neal Dunn, M.D.

R

Florida – District 2

Ranking Member Health

Diana DeGette

D

Colorado – District 1

Morgan Griffith

R

Virginia – District 9

Gus Bilirakis

R

Florida – District 12

Dan Crenshaw

R

Texas – District 2

John Joyce

R

Pennsylvania – District 13

Troy Balderson

R

Ohio – District 12

Diana Harshbarger

R

Tennessee – District 1

Mariannette Miller-Meeks

R

Iowa – District 1

Kat Cammack

R

Florida – District 3

Jay Obernolte

R

California – District 23

John James

R

Michigan – District 10

Cliff Bentz

R

Oregon – District 2

Erin Houchin

R

Indiana – District 9

Nick Langworthy

R

New York – District 23

Tom Kean

R

New Jersey – District 7

Michael Rulli

R

Ohio – District 6

Brett Guthrie

R

Kentucky – District 2

Raul Ruiz

D

California – District 25

Debbie Dingell

D

Michigan – District 6

Robin Kelly

D

Illinois – District 2

Nanette Diaz Barragán

D

California – District 44

Kim Schrier

D

Washington – District 8

Lori Trahan

D

Massachusetts – District 3

Marc Veasey

D

Texas – District 33

Lizzie Fletcher

D

Texas – District 7

Alexandria Ocasio-Cortez

D

New York – District 14

Jake Auchincloss

D

Massachusetts – District 4

Troy Carter

D

Louisiana – District 2

Greg Landsman

D

Ohio – District 1

Frank Pallone

D

New Jersey – District 6

Recent Letters


Dec 19, 2024
Press Release

E&C Republicans Request HHS Watchdog Investigate Promotion of Gender Transition Procedures for Children

Washington, D.C. — In a new letter to Department of Health and Human Services (HHS) Inspector General Christi Grimm, House Energy and Commerce Committee Republicans requested an investigation into the strength, quality, and types of evidence-based scientific and pediatric medical literature relied on by the department to promote gender transition procedures for children.  KEY LETTER EXCERPT:  “As the agency responsible for safeguarding the health and well-being of Americans, all of HHS’s medical treatment recommendations, especially medical treatment recommendations for children, should be based on rigorous and well-established research, such as randomized controlled trials, that have definitively illustrated the long-term benefits of gender affirming care treatments.”  BACKGROUND:  Under the Biden administration, HHS has advocated for sex reassignment procedures on minors, including the use of serum puberty blockers, which have historically been used to treat children with precocious puberty (i.e., early onset puberty affecting about one percent of U.S. children) and sex offenders.   Puberty blockers, however, are known to stunt normal childhood development in children unaffected by precocious puberty.  HHS officials contend that sex reassignment procedures on minors are an unanimously accepted medical practice.  HHS Secretary Becerra testified before Congress that “every major medical association,” “medical journals,” and “scientific and medical evidence” has demonstrated the benefits of transitioning children’s biological sex.  When asked, via a Freedom of Information Act request, for the underlying scientific or medical basis for its position, HHS was only able to produce a two-page brochure that was already publicly available.  In contrast to HHS, a growing body of literature from medical experts and authorities around the world, including those in Europe, caution against performing such procedures on minors.   Courts and government health agencies responsible for determining child welfare have sought to limit child sex reassignment procedures.   Other countries have banned these interventions and surgeries on minors altogether.  An article published in the British Journal of Medicine found “there is great uncertainty about the effects of puberty blockers, cross-sex hormones, and surgeries in young people.”   A court in the United Kingdom noted the obvious about administering puberty blocking chemicals onto children: “[i]t is highly unlikely that a child aged 13 or under would be competent to give consent to the administration of puberty blockers. It is doubtful that a child aged 14 or 15 could understand and weigh the long-term risks and consequences of the administration of puberty blockers.”  In April 2024, the Cass Review , an independent review of gender identity services for children and young people, commissioned by the National Health Service England, found “[w]hile a considerable amount of research has been published in this field, systematic evidence reviews demonstrated the poor quality of the published studies, meaning there is not a reliable evidence base upon which to make clinical decisions, or for children and their families to make informed choices.”   The Cass Review also found that “[t]he rationale for early puberty suppression remains unclear, with weak evidence regarding the impact on gender dysphoria, mental or psychosocial health,” as well as unknown effects on cognitive and psychosexual development.  In August 2024, the American Society of Plastic Surgeons (ASPS) became the first major U.S. medical association to express caution on the use of gender surgery for gender dysphoria in adolescents. In its formal statement, the association stated: “ASPS currently understands that there is considerable uncertainty as to the long-term efficacy for the use of chest and genital surgical interventions for the treatment of adolescents with gender dysphoria, and the existing evidence base is viewed as low quality/low certainty. This patient population requires specific considerations.”   The letter was signed by Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA), Rep. Dan Crenshaw (R-TX), Rep. Gus Bilirakis (R-FL), Rep. Buddy Carter (R-GA), Rep. Gary Palmer (R-AL), Rep. Neal Dunn (R-FL), Rep. Randy Weber (R-TX), Rep. Troy Balderson (R-OH), Rep. August Pfluger (R-TX), Rep. Diana Harshbarger (R-TN), and Rep. Kat Cammack (R-FL).  CLICK HERE to read the letter.



Nov 22, 2024
Press Release

E&C, E&W Republicans Press Gladstone Institutes for Information Regarding Internal Antisemitism

House Republicans scrutinize government grant funding recipients that fail to protect individuals from antisemitism Washington, D.C. — In a new letter to J. David Gladstone Institutes President Dr. Deepak Srivastava, the House Committee on Energy and Commerce (E&C) and House Committee on Education and the Workforce (E&W) have requested information about ongoing and pervasive acts of antisemitic harassment and intimidation at Gladstone and its leadership’s insufficient response to these acts. The letter is signed by E&C Chair Cathy McMorris Rodgers (R-WA), E&C Subcommittee on Health Chair Brett Guthrie (R-KY), E&C Oversight and Investigations Subcommittee Chair Morgan Griffith (R-VA), E&W Chair Virginia Foxx (R-NC), and E&W Subcommittee on Higher Education and Workforce Development Chair Burgess Owens (R-UT).  KEY LETTER EXCERPTS: “The Gladstone Institutes, an independent biomedical research organization, claims that it takes an active stance against serious issues like discrimination and harassment and aims to ‘ensure all community members at Gladstone feel included’ and that the Institutes will aim to ‘implement accountability measures and reinforce Gladstone’s commitment to having an environment free of harassment.’ However, these values do not seem to be reflected in the actions of leadership in response to recent concerns of antisemitic harassment and discrimination within the Institutes.” [...] “The reports of antisemitic harassment at Gladstone coupled with the inadequate response by leadership is concerning to the Committees. Failing to act decisively to ensure a safe environment for all trainees, faculty, and staff is a grave dereliction of your responsibilities as President of Gladstone.” “Failing to comply with basic safety protections for members of Gladstone or failure to respond appropriately to and prevent harassment and discrimination, no matter the cause, may be grounds to withhold federal funds from the university. Congress has an obligation to exercise oversight of recipients of federal funds when blatant and ongoing Title VI violations appear to be happening. If Congress determines an institution of higher education/research is blatantly ignoring its legal responsibilities, we may consider rescinding research and development funds previously appropriated.” BACKGROUND ON TAXPAYER FUNDING: Gladstone received more than $41 million in funding from the NIH in Fiscal Year 2023, not including potential taxpayer funding that individual faculty may have received through their affiliation with the University of California, San Francisco (UCSF) or any other affiliated universities.   According to the NIH’s Grant Policy Statement, any institution receiving federal funds must assure work environments are free of discriminatory harassment and are safe and conducive to high-quality work.  Institutions receiving federal taxpayer financial assistance—such as NIH grants—are prohibited from discriminating based on a variety of categories, including national origin.   These laws also protect members of the institution who are or are perceived to be members of a group with shared ancestry, such as students/trainees of Jewish heritage. BACKGROUND ON INSTANCES OF ANTISEMITISM : Two days after the October 7, 2023, Hamas terrorist attack, a graduate student working in a lab within Gladstone sent an antisemitic email to all Gladstone faculty, trainees, and staff falsely stating that the attack on innocent Israeli civilians was “the resistance in Gaza launch[ing] a surprise attack against Israel, taking occupation soldiers hostage, taking over Israeli military vehicles, and gain[ing] control over illegal Israeli settlements.”  The email goes on to claim that all casualties resulting from Palestinian actions are the responsibility of Israel.  Immediately following this mass email, members of the Gladstone faculty began contacting the Gladstone Institutes’ President and other leadership, appalled by the language of the email, concerned for their safety and worried that the email could be seen as an incitement to violence.  Jewish members of the Institutes also expressed their deep, personal pain following the Hamas attack, as some members had family or friends reported killed or missing directly after the attack.  These fears—including fears of being attacked in the lab by the author of this cruel and antagonistic email—were shared directly with President Srivastava.  Despite this, Gladstone leadership did not issue a public statement or position against antisemitism to quell fears of Jewish faculty and trainees.  In May 2024, the Center for Combatting Antisemitism sent President Srivastava a letter requesting administrative action to address the hostile environment and disparate treatment of Jewish members at Gladstone.  This letter noted that Gladstone refused to acknowledge Jewish American Heritage Month, Passover, or Holocaust Remembrance Day, despite sending official celebratory emails and holding events for other religious, ethnic, or national holidays, including Black History Month, International Women’s Day, and Ramadan.  The Center followed up with Gladstone several times, but never received a response.  Jewish faculty and trainees have conveyed to leadership within Gladstone instances of antisemitic harassment and discrimination, which faculty and trainees believe were not taken seriously, making some feel uneasy about speaking out.  For example, per a publicly available Fair Employment and Housing Act complaint to the California Civil Rights Division, a Jewish faculty member openly discussed fellow faculty using racial stereotypes, including comments about a “Jewish nose.”  When these comments were brought to human resources, no investigation occurred.  Instead, the complainant was subsequently targeted with an investigation ultimately deemed to be unwarranted.  Then, following the complainant’s post-October 7th advocacy on behalf of Jewish faculty and trainees, the complainant was threatened repeatedly with career-ending termination, allegedly in an attempt to extort a resignation.  When the threats did not have their desired effect, Gladstone placed the complainant on administrative leave and removed the complainant’s electronic access to email and files but also physical access to the complainant’s lab, removing all ability to conduct work on an NIH-funded grant.  Gladstone ultimately paid an undisclosed sum to settle the matter and avoid litigation.  To elevate concerns regarding widespread, ongoing discrimination, Jewish faculty and trainees requested permission to bring in a speaker related to antisemitism.  Other minority groups had previously been given permission to bring in similar anti-racism speakers.  However, while leadership stated it would look into the idea, ultimately no speaker was brought, and no program was launched regarding antisemitism. BACKGROUND ON AFFILIATIONS WITH OTHER INSTITUTIONS UNDER INVESTIGATION : Gladstone Institutes is affiliated with other institutions under congressional investigation.  For example, Gladstone is an affiliate of the UCSF, which is undergoing congressional investigation for reports of antisemitism within the university, medical school, and medical centers.  Most of Gladstone’s principal investigators are also faculty at UCSF, and the Institutes provide research positions and opportunities for graduate students from UCSF.  Moreover, there is a joint institute—the Gladstone-UCSF Institute of Genomic Immunology—further linking the two institutions.  Gladstone is also affiliated with the University of California, Berkeley and Stanford University, both of which are also under investigation for concerns related to antisemitism. CLICK HERE to read the full letter.



Nov 12, 2024
Press Release

E&C Republicans Ask GAO to Assess Structure of CDC, FDA, and NIH Lab Safety Offices

Washington, D.C. — In a new letter to Government Accountability Office Comptroller General Gene Dodaro, House Energy and Commerce Committee Republicans have requested an examination of the structure of laboratory safety programs at the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH).  The letter was signed by Committee Chair Cathy McMorris Rodgers (R-WA), Subcommittee on Health Chair Brett Guthrie (R-KY), and Subcommittee on Oversight and Investigations Chair Morgan Griffith (R-VA).  KEY LETTER EXCERPT :  This committee remains concerned about the effectiveness of the oversight HHS and its agencies provide to the laboratories they own and operate. In addition to numerous GAO recommendations that remain unimplemented by the FDA, both the CDC and the FDA recently announced organizational reforms to their laboratory safety and security functions, and it is not clear whether these changes will strengthen oversight or create new undue risk. The FDA has, for example, reorganized several of its laboratories such that they now fall within the Office of the Chief Scientist. This raises potential independence concerns, as the FDA’s laboratory safety and security functions report to the same office.  BACKGROUND :  The mission of the U.S. Department of Health and Human Services (HHS) is to enhance the health and well-being of all Americans.   As such, HHS is most directly involved in leading public health preparedness and response efforts, as well as associated research.   However, past safety lapses involving the CDC, the FDA, and the NIH have been the result of multiple breakdowns in compliance with established policies coupled with inadequate oversight.   For example, in July 2014, boxes containing decades-old vials of smallpox and other hazardous biological agents were found in a storage space of an FDA laboratory on the NIH’s campus. GAO and other reviews resulted in numerous findings and recommendations to strengthen laboratory safety and security, which led to changes to the way HHS and its agencies oversee their laboratories.   Likewise, GAO and other reviews have highlighted the importance of laboratory science and security in the handling of federal select agents and other dangerous pathogens in research.  CLICK HERE to read the full letter.